Quellen und Literatur
Aebi S, Assereto R, Lauterburg BH. High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Investig 1991;21:103–110
Aggarwal BB, Sundaram C, Malani N et al. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007;595:1–75
Alexander J, Tinkov A, Strand TA. Early nutritional interventions with zinc, selenium and vitamin D for raising anti-viral resistance against progressive COVID-19. Nutrients 2020;12(8):2358
Assaf G, Davis H, McCorkell L et al. What does COVID-19 recovery actually look like? 2020 May 11. https://patientresearchcovid19.com/research/report-1/ (Abruf 31.5.2021)
Awa WL, Plaumann M, Walter U. Burnout prevention: a review of intervention programs. Patient Educ Couns 2010;78(2):184–190
Ayoubkhani D. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021?s=09 (Abruf 31.5.2021)
Ayoubkhani D, Khunti K, Nafilyan V et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 2021; 372:n693
Baig AM. Chronic COVID Syndrome: need for an appropriate medical terminology for Long-COVID and COVID Long-Haulers. J Med Virol 2021;93(5):2555–2556
Bansal A, Bradley A, Bishop K et al. Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun 2012;26(1):24–31
Baumann FT, Wajda S, Bloch W. Einflüsse von körperlichen Aktivitäten auf das Fatiguesyndrom von Brustkrebspatientinnen. Z Komplementärmed 2009;1:14–18
Bermano G, Méplan, Mercer DK et al. Selenium and viral infection: are there lessons for COVID-19? Br J Nutr 2021;125(6):618–627
Böhm U, Reuss F. Zellschutz – Entgiftung – Prävention. Die gesundheitliche Bedeutung von Glutathion. Uni-Med Verlag, Bremen 2013
Brundu S, Palma L, Picceri GG et al. Glutathione depletion is linked with Th2 polarization in mice with a retrovirus-induced immunodeficiency syndrome, murine AIDS: role of proglutathione molecules as immunotherapeutics. J Virol 2016;90:7118–7130
Buhl R, Vogelmeier C, Crittenden M et al. Augmentation of reduced glutathione levels in the epithelial lining fluid of the lower respiratory tract by direct aerosol administration of glutathione. Proc Natl Acad Sci USA 1990;87:4063–4067
Burgerstein L. Handbuch Nährstoffe. 12. Auflage. Trias Verlag, Stuttgart 2012
Burkhard H, Wahle M. Postvirales Fatiguesyndrom. In: Doerr HW, Gerlich WH (Hrsg). Medizinische Virologie. Grundlagen, Diagnostik, Prävention und Therapie viraler Erkrankungen. 2. Auflage. Thieme, Stuttgart, New York 2010, S. 256
Cacciatore I, Cornacchia C, Pinnen F et al. Prodrug approach for increasing cellular glutathione levels. Molecules 2012;15:1242–1264
Cai J, Chen Y, Seth S et al. Inhibition of influenza infection by glutathione. Free Radic Biol Med 2003;34(7):928–936
Campbell J. Fears over thousands of „long haul“ COVID-19 sufferers. Scotsman 2020 Jun 15. https://www.scotsman.com/regions/fears-over-thousands-long-haul-COVID-19-sufferers-2884703. (Abruf 31.5.2021)
Cao R, Hu H, Li Y et al. Anti-SARS-CoV-2 potential of artemisinins in vitro. ACS Infect Dis 2020;6(9):2524–2531
Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324(6):603–605
Chatterjee A. Reduced glutathione: a radioprotector or a modulator of DNA-repair activity? Nutrients 2013;5(2):525–542
Chen T, Song J, Liu H et al. Positive Epstein-Barr virus detection in corona virus disease 2019 (COVID-19) patients. Available at SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3555268 (Abruf 31.5.2021)
Cheong DHJ, Tan DWS, Wong FWS et al. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases. Pharmacol Res 2020;158:104901
Craig DJ. How COVID-19 could reveal the secrets of chronic fatigue syndrome. Fall 2020. https://magazine.columbia.edu/article/how-COVID-19-could-reveal-secrets-chronic-fatigue-syndrome (Abruf 31.5.2021)
Cramer-Scharnagl D. Glutathion. Unverzichtbar für die Entgiftung, effektiv bei chronischer Erschöpfung, schützt Mitochondrien und Zellen. VAK Verlag, Kirchzarten bei Freiburg 2015
Dröge W, Breitkreutz R. Glutathione and immune function. Proc Nutr Soc 2000;59:595–600
Efferth T, Romero MR, Wolf DG et al. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 2008;47(6):804–811
Fanelli S, Francioso A, Cavallaro RA et al. Oral administration of s-acetyl-glutathione: impact on the levels of glutathione in plasma and in erythrocytes of healthy volunteers. Int J Clin Nutr Diet 2018;4:134
Franke F, Ferse C, Kreye J et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun 2021;93:415–419
Fraternale A, Brundu S, Magnani M. Glutathione and glutathione derivates in immunotherapy. Biol Chem 2017;398:261–275
Fraternale A, Paoletti MF, Casabianca A et al. Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules. Curr Med Chem 2006;13:1749–1755
Fraternale A, Paoletti MF, Casabianca A et al. Inhibition of murine AIDS by pro-glutathione (GSH) molecules. Antiviral Res 2008;77:120–127
Galmés S, Serra F, Palou A. Current state of evidence: influence of nutritional and nutrigenetic factors on immunity in the COVID-19 pandemic framework. Nutrients 2020;12(9):2738
Garner P. COVID-19 and fatigue – a game of snakes and ladders. BMJ Opinion 2020 May 19. https://blogs.bmj.com/bmj/2020/05/19/paul-garner-COVID-19-and-fatigue-a-game-of-snakes-and-ladders/ (Abruf 31.5.2021)
Geiger R. S-Acetyl-Glutathion (Eumetabol®) versus reduziertes Glutathion: Vergleichsstudie zur In-vivo-Halbwertszeit. (Im Druck)
Gendrot M, Andreani J, Boxberger M et al. Antimalarial drugs inhibit the replication of SARS-CoV-2: an in vitro evaluation. Travel Med Infect Dis 2020;37:101873
Guloyan V, Oganesian B, Baghdasaryan N et al. Glutathione supplementation as an adjunctive therapy in COVID-19. Antioxidants (Basel) 2020;9(10):914
Halpin S, O’Connor R, Sivan M. Long COVID and chronic COVID syndromes. J Med Virol 2021;93(3):1242–1243
Halpin SJ, McIvor C, Whyatt G et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol 2021;93(2):1013–1022
Harding L. „It feels endless“: four women struggling to recover from COVID-19. Guardian 2020 Jun 7. https://www.theguardian.com/world/2020/jun/07/it-feels-endless-four-women-struggling-to-recover-from-covid-19-coronavirus-symptoms (Abruf 31.5.2021)
Herridge MS, Cheung AM, Tansey CM et al. One-year outcomes in survivors of the acute respiratory distress syndrome. NEJM 2003;348:683–693
Hiffler L, Rakotoambinina B. Selenium and RNA virus interactions: potential implications for SARS-CoV-2 Infection (COVID-19). Front Nutr 2020;7:164
Ho WE, Peh HY, Chan TK et al. Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol Ther 2014;142(1):126–139
Hofman M, Ryan JL, Figueroa-Moseley CD et al. Cancer-related fatigue. The scale of the problem. Oncologist 2007;12(Suppl.1):4–10
Hooper PL. COVID-19 and heme oxygenase: novel insight into the disease and potential therapies. Cell Stress Chaperones 2020;25(5):707–710
Horneber M, Fischer I, Dimeo F et al. Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment. Dtsch Arztebl Int 2012;109(9):161–172
Horowitz RI, Freeman PR, Bruzzese J. Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia. Respir Med Case Rep 2020;30:101063
Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506
Ilyas S, Rehmann A. Oxidative stress, glutathione level and antioxidant response to heavy metals in multi-resistant pathogen, Candida tropicalis. Environ Monit Assess 2015;187(1):4115
Islam MF, Cotler J, Jason LA. Post‐viral fatigue and COVID‐19: lessons from past epidemics. Fatigue: Biomed, Health Behav 2020;8(2):61–69
Kamal M, Abo Omirah M, Hussein A et al. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract 2020 Sep 29:e13746
Kerstholt M, Vrijmoeth H, Lachmandas E et al. Role of glutathione metabolism in host defense against Borrelia burgdorferi infection. Proc Natl Acad Sci USA 2018;115(10):E2320–E2328
Khanfar A, Al Qaroot B. Could glutathione depletion be the Trojan horse of COVID-19 mortality? Eur Rev Med Pharmacol Sci 2020;24:12500–12509
Kingstone T, Taylor AK, O’Donnell CA et al. Finding the „right“ GP: a qualitative study of the experiences of people with long-COVID. BJGP Open 2020;4(5)
Klok FA, Boon GJAM, Barco S et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. Eur Respir J 2020;56(1):2001494
Kompaktlexion der Biologie: Glutathion. Spektrum Verlag 2001. http://www.spektrum.de/lexikon/biologie-kompakt/glutathion/4938 (Abruf 31.5.2021)
Kristiansen MS, Stabursvik J, O’Leary EC et al. Clinical symptoms and markers of disease mechanisms in adolescent chronic fatigue following Epstein-Barr virus infection: an exploratory cross-sectional study. Brain Behav Immun 2019;80:551–563
Kuklinski B, Schmionek A. Mitochondrientherapie – die Alternative. Aurum Verlag, Bielefeld 2014
Ky B, Mann DL. COVID-19 clinical trials: a primer for the cardiovascular and cardio-oncology communities. J Am Coll Cardiol Basic Trans Science 2020;5:501–517
Lam MH, Wing YK, Yu MW et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors – long-term follow-up. Arch Intern Med 2009;169(22):2142–2147
Lamprecht B. Gibt es ein Post-COVID-Syndrom? Pneumologe (Berl) 2020;17:398–405
Lima JE. The role of glutathione in viral diseases of the central nervous system. In: Erkekoglu P, Kocer-Gumusel B (Ed.) Glutathione in health and disease. IntechOpen, London 2018, 65–81
Lin Y, Wu F Xie Z et al. [Clinical study of artesunate in the treatment of coronavirus disease 2019]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020;32(4):417–420
Linke J. Cancer Fatigue und gestörte Ruhe/Aktivitäts-Regulation bei Mammakarzinom-Patientinnen. Eine explorative Fall-Kontroll-Studie. Univ. Diss., Med. Fakultät Charité – Universitätsmedizin, Berlin 2009
Lyons D, Frampton M, Naqvi S et al. Fallout from the COVID-19 pandemic – should we prepare for a tsunami of post viral depression? Ir J Psychol Med 2020;37(4):295–300
Magnani M, Fraternale A, Casabianca A et al. Antiretroviral effect of combined zidovudine and reduced glutathione therapy in murine AIDS. AIDS Res Hum Retroviruses 1997;13:1093–1099
Mandal S, Barnett J, Brill SE et al. „Long-COVID“: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 2020 Nov 10;thoraxjnl-2020-215818. doi: 10.1136/thoraxjnl-2020-215818. Online ahead of print
Martin M. Labormedizin in der Naturheilkunde. Elsevier, München 2006
Martineau AR, Jolliffe DA, Hooper RL et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017;356:i6583
Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post‐SARS syndrome; a case‐controlled study. BMC Neurology 2011;11(1):37
Moreno-Sánchez R, Rodríguez-Enríquez S, Jasso-Chávez R et al. Biochemistry and physiology of heavy metal resistance and accumulation in euglena. Adv Exp Med Biol 2017;979:91–121
Morris D, Khurasany M, Nguyen T et al. Glutathione and infection. Biochim Biophys Acta 2013;1830(5):3329–3349
Mrityunjaya M, Pavithra V, Neelam R et al. Immune-boosting, antioxidant and anti-inflammatory food supplements targeting pathogenesis of COVID-19. Front Immunol 2020;11:570122
Myhill S et al. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009;2(1):1–16
Neufeld KJ, Leoutsakos J-MS, Yan H et al. Fatigue symptoms during the first year following ARDS. Chest 2020;158(3):999–1007
Ngai JC, Ko FW, Ng SS et al. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology 2010;15:543–550
O’Connor CM. COVID-19 fatigue: not so fast. JACC Heart Fail 2020;8(7):592–594
Pacht ER, Timerman AP, Lykens MG et al. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest 1991;100(5):1397–1403
Palamara AT, Brand G, Rossi L et al. New synthetic glutathione derivatives with increased antiviral activities. Antivir Chem Chemother 2004;15:77–85
Palamara AT, Garaci E, Rotilio G et al. Inhibition of murine AIDS by reduced glutathione. AIDS Res Hum Retroviruses 1996;12:1373–1381
Palamara AT, Perno CF, Ciriolo MR et al. Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication. Antiviral Res 1995;27:237–253
Perrin R, Riste L, Hann M et al. Into the looking glass: post-viral syndrome post COVID-19. Med Hypotheses 2020;144:110055
Polonikov A. Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in COVID-19 patients. ACS Infect Dis 2020;6(7):1558–1562
Prasad S, Tyagi AK. Curcumin and its analogues: a potential natural compound against HIV infection and AIDS. Food Funct 2015;6(11):3412–3419
Pressemitteilung EMEA (European ME Alliance) vom 23.11.2008. http://www.cfs-aktuell.de/emea.htm (Abruf 31.5.2021)
Psychische Erkrankungen. Wie Immunsystem und Psyche zusammenhängen. https://www.gesundheitsstadt-berlin.de/wie-immunsystem-und-psyche-zusammenhaengen-5138/ (Abruf 31.5.2021)
Raffetin A, Bruneel F, Roussel C et al. Use of artesunate in non-malarial indications. Med Mal Infect 2018;48(4):238–249
Reineberger S. Kranker Körper – kranke Seele. Spektrum Verlag 2016. http://www.spektrum.de/news/wenn-das-immunsystem-die-psyche-krank-macht/1422056 (Abruf 31.5.2021)
Richie JP Jr, Nichenametla S, Neidig W et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr 2015;54;2:251–263
Rocha FAC, de Assis MR. Curcumin as a potential treatment for COVID-19. Phytother Res 2020;34(9):2085–2087
Rogers JP, Chesney E, Oliver D et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020;7(7):611–627
Romero MR, Efferth T, Serrano MA et al. Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an „in vitro“ replicative system. Antiviral Res 2005;68(2):75–83
Roy A, Sarkar B, Celik C et al. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19? Phytother Res 2020;34(10):2425–2428
Rubin R. As their numbers grow, COVID-19 „long haulers“ stump experts. JAMA 2020;324(14):1381–1383
Rubino F, Amiel SA, Zimmet P et al. New-onset diabetes in COVID-19. N Engl J Med 2020;383(8):789–790
Salisbury H. When will we be well again? BMJ 2020;369:m2490
Schultheiß C, Paschold L, Simnica D et al. Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease. Immunity 2020;53(2):442–455.e4
Silvagno F, Vernone A, Pescarmona GP. The role of glutathione in protecting against the severe inflammatory response triggered by COVID-19. Antioxidants (Basel) 2020;9(7):624
Simpson R, Robinson L. Rehabilitation after critical illness in people with COVID-19 infection. Am J Phys Med Rehabil 2020;99:470–474
Soni VK, Mehta A, Ratre YK et al. Curcumin, a traditional spice component, can hold the promise against COVID-19? Eur J Pharmacol 2020;886:173551
Stone P, Richards M, Herr RA et al. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 2000;11:561–567
Studie zur Gesundheit Erwachsener in Deutschland (DEGS). Robert Koch-Institut 2013. http://www.rki.de/DE/Content/Gesundheitsmonitoring/Studien/Degs/degs_w1/DEGS1-Ergebnisse.pdf?__blob=publicationFile (Abruf 31.5.2021)
Tansey CM, Louie M, Loeb M et al. One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med 2007;167:1312–1320
Tenforde MW, Kim SS, Lindsell CJ et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network – United States, March–June 2020. MMWR Morb Mortal Wkly Rep 2020;69(30):993–998
Teymoori-Rad M, Shokri F, Salimi V et al. The interplay between vitamin D and viral infections. Rev Med Virol 2019;29(2):e2032
Tian S, Hu N, Lou J et al. Characteristics of COVID-19 infection in Beijing. J Infect 2020;80(4):401–406
Townsend L, Dyer AH, Jones K et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS ONE 2020;15(11):e0240784
Uzun T, Toptas O. Artesunate: could be an alternative drug to chloroquine in COVID-19 treatment? Chin Med 2020;15:54
Valencia E, Hardy G, Marin A. Glutathione – nutritional and pharmacologic viewpoints. Part I–VI. Part I: Nutrition 2001;17(5):428–429; Part II: Nutrition 2001;17(6):485–486; Part III: Nutrition 2001;17(7–8):696–697; Part IV: Nutrition 2001;17(9):783–784; Part V: Nutrition 2001;17(11–12):978, Erratum in: Nutrition 2002;18(3):292; Part VI: Nutrition 2002;18(3):291–292
Valizadeh H, Abdolmohammadi-Vahid S, Danshina S et al. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int Immunopharmacol 2020 Oct 20;89(Pt B):107088
Varga Z, Flammer AJ, Steiger P. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395(10234):1417–1418
Vogel JU, Cinatl J, Dauletbaev N et al. Effects of S-acetylglutathione in cell and animal model of herpes simplex virus type 1 infection. Med Microbiol Immunol 2005;194:55–59
Vogelzang NJ, Breitbart W, Cella D et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol 1997;34:4–12
Voskresenska N, Voicehovska J, Babikovs S et al. Glutathione level in community-acquired pneumonia patients. Eur Respir J 2017;50(Suppl.61):PA988
Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061–1069
Wendel A, Cikryt P. The level and half-life of glutathione in human plasma. FEBS Letters 1980;120:209–211
Williams FMK, Muirhead N, Pariante C. COVID-19 and chronic fatigue. BMJ 2020;370:m2922
Wilson C. Concern coronavirus may trigger post-viral fatigue syndromes. NewScientist 2020;246(3278):10–11
Wise J. Long COVID: doctors call for research and surveillance to capture disease. BMJ 2020;370:m3586
Witschi A, Reddy S, Stofer B et al. The systemic availability of oral glutathione. Eur J Clin Pharmacol 1993;43(6):667–669
Working Group on CFS/ME (Ed.) A report of the CFS/ME working group. Report to the Chief Medical Officer of an independent working group. British Department of Health, UK online, 11.01.2002. http://www.erythos.com/gibsonenquiry/Docs/CMOreport.pdf (Abruf 31.5.2021)
Wu X, Cobbina SJ, Mao G et al. (2016) A review of toxicity and mechanisms of individual and mixtures of heavy metals in the environment. Environ Sci Pollut Res Int 23(9):8244–8259
Xu XW, Wu XX, Jiang XG et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606
Zahedipour F, Hosseini SA, Sathyapalan T et al. Potential effects of curcumin in the treatment of COVID-19 infection. Phytother Res 2020;34(11):2911–2920
Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020;75(7):1730–1741
Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets 2011;12(3):332–347
Zhu J, Ji P, Pang J et al. Clinical characteristics of 3062 COVID-19 patients: a meta-analysis. J Med Virol 2020;92(10):1902–1914
Zhu J, Zhong Z, Ji P et al. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Fam Med Community Health 2020;8(2):e000406
Eumetabol® kaufen
Patienten und Therapeuten können die Eumetabol® Infusionen direkt bei der herstellenden Apotheke bestellen. Die Viktoria Apotheke in Saarbrücken liefert schnell und berät gern.
Infos für Patienten
In unserer Patientenbroschüre haben wir für Sie die wichtigsten Informationen und Quellen zur Eumetabol®-Infusionstherapie mit S-Acetyl-Glutathion zusammengefasst.
Tipp: Laborkontrolle
Vor Beginn und im Verlauf der Glutathion-Zelltherapie mit Eumetabol® ist die Untersuchung der Blutwerte empfehlenswert. So lässt sich die niedrigste und damit kostengünstigste Dosierung definieren.
Labor-Downloads
Transparenz ist uns wichtig: Wir bieten Ihnen die Untersuchungs-Anforderung bei den RD Laboratorien und die aktuelle Preisliste des Labors zum direkten Download an.
Therapeuten finden
Bei der Suche nach einem Therapeuten mit Erfahrung in der Glutathion-Therapie mit S-Acetyl-Glutathion nach Dr. med. Gerhard Ohlenschläger® ist Ihnen die Viktoria Apotheke gern behilflich.
Weitere Informationen
Das Glutathion-System und die Glutathion-Therapie sind gut erforscht. Hier finden Sie die wichtigsten und interessantesten Studien und Literaturhinweise.